These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 26701846)

  • 1. Submolecular recognition of the C-terminal domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients.
    Oshima M; Deitiker P; Jankovic J; Aoki KR; Atassi MZ
    Immunobiology; 2016 Apr; 221(4):568-76. PubMed ID: 26701846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Regions on the Light Chain of Botulinum Neurotoxin Type A Recognized by T Cells from Toxin-Treated Cervical Dystonia Patients. The Complete Human T-Cell Recognition Map of the Toxin Molecule.
    Oshima M; Deitiker P; Jankovic J; Atassi MZ
    Immunol Invest; 2018 Jan; 47(1):18-39. PubMed ID: 28891721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Submolecular recognition regions of the H
    Oshima M; Deitiker P; Jankovic J; Atassi MZ
    J Neuroimmunol; 2016 Nov; 300():36-46. PubMed ID: 27806874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule.
    Atassi MZ; Jankovic J; Steward LE; Aoki KR; Dolimbek BZ
    Immunobiology; 2012 Jan; 217(1):17-27. PubMed ID: 21962573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regions recognized on the light chain of botulinum neurotoxin type A by T lymphocytes of SJL and BALB/c mice primed with inactivated toxin.
    Oshima M; Aoki KR; Atassi MZ
    Immunobiology; 2014 Dec; 219(12):950-7. PubMed ID: 25151501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody and T cell recognition of the light chain of botulinum neurotoxin A in two high-responder mouse strains.
    Atassi MZ; Oshima M; Dolimbek BZ; Aoki KR
    Immunobiology; 2012 Jan; 217(1):1-7. PubMed ID: 22015045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A.
    Dolimbek BZ; Aoki KR; Steward LE; Jankovic J; Atassi MZ
    Mol Immunol; 2007 Feb; 44(5):1029-41. PubMed ID: 16647121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping of the antibody and T cell recognition profiles of the HN domain (residues 449-859) of the heavy chain of botulinum neurotoxin A in two high-responder mouse strains.
    Dolimbek GS; Dolimbek BZ; Aoki KR; Atassi MZ
    Immunol Invest; 2005; 34(2):119-42. PubMed ID: 15921155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Localization of the regions on the C-terminal domain of the heavy chain of botulinum A recognized by T lymphocytes and by antibodies after immunization of mice with pentavalent toxoid.
    Rosenberg JS; Middlebrook JL; Atassi MZ
    Immunol Invest; 1997 Jun; 26(4):491-504. PubMed ID: 9246568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies.
    Atassi MZ; Dolimbek BZ; Jankovic J; Steward LE; Aoki KR
    Immunobiology; 2011 Jul; 216(7):782-92. PubMed ID: 21281977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment.
    Atassi MZ; Dolimbek BZ; Jankovic J; Steward LE; Aoki KR
    Mol Immunol; 2008 Sep; 45(15):3878-88. PubMed ID: 18676021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The C-terminal heavy-chain domain of botulinum neurotoxin a is not the only site that binds neurons, as the N-terminal heavy-chain domain also plays a very active role in toxin-cell binding and interactions.
    Ayyar BV; Aoki KR; Atassi MZ
    Infect Immun; 2015 Apr; 83(4):1465-76. PubMed ID: 25624352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping of the antibody-binding regions on the HN-domain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the H-chain of botulinum neurotoxin A.
    Atassi MZ; Dolimbek BZ
    Protein J; 2004 Jan; 23(1):39-52. PubMed ID: 15115181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display.
    Levy R; Forsyth CM; LaPorte SL; Geren IN; Smith LA; Marks JD
    J Mol Biol; 2007 Jan; 365(1):196-210. PubMed ID: 17059824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B.
    Oshima M; Deitiker PR; Jankovic J; Duane DD; Aoki KR; Atassi MZ
    J Neuroimmunol; 2011 Dec; 240-241():121-8. PubMed ID: 22079193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune recognition of botulinum neurotoxin type A: regions recognized by T cells and antibodies against the protective H(C) fragment (residues 855-1296) of the toxin.
    Oshima M; Hayakari M; Middlebrook JL; Atassi MZ
    Mol Immunol; 1997 Oct; 34(14):1031-40. PubMed ID: 9488054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with antitoxin antibodies from three host species.
    Atassi MZ; Dolimbek BZ; Hayakari M; Middlebrook JL; Whitney B; Oshima M
    J Protein Chem; 1996 Oct; 15(7):691-700. PubMed ID: 8968960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies against a synthetic peptide designed to mimic a surface area of the H chain of botulinum neurotoxin A.
    Atassi MZ; Dolimbek BZ; Steward LE; Aoki KR
    Immunol Lett; 2012 Feb; 142(1-2):20-7. PubMed ID: 22123395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Location of the synaptosome-binding regions on botulinum neurotoxin B.
    Dolimbek BZ; Steward LE; Aoki KR; Atassi MZ
    Biochemistry; 2012 Jan; 51(1):316-28. PubMed ID: 22146011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human T-cell responses to botulinum neurotoxin: proliferative responses in vitro of lymphocytes from botulinum neurotoxin A-treated movement disorder patients.
    Oshima M; Deitiker PR; Jankovic J; Duane DD; Aoki KR; Atassi MZ
    J Neuroimmunol; 2011 Aug; 237(1-2):66-72. PubMed ID: 21737146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.